Literature DB >> 28983797

Clinical factors associated with decision to recommend methylphenidate treatment for children with ADHD in France.

Elodie Courtabessis1, Florence Pupier2, Laurie Surig2, Marie-Christine Picot3,4, Erika Nogué3, Valérie Macioce3, Elizabeth Stein2, Diane Purper-Ouakil2.   

Abstract

European guidelines advise on best practices for the diagnosis and non-pharmacological and pharmacological treatment of attention-deficit hyperactivity disorder (ADHD). This study aimed to (1) assess whether clinician's decisions to initiate methylphenidate treatment in children diagnosed with ADHD are in accordance with European guidelines and (2) identify clinical factors associated with the decision to recommend methylphenidate prescription. 5 to 13-year-old patients with an ADHD diagnosis were consecutively evaluated in an outpatient child and adolescent psychiatry clinic in France. Patients underwent a multidisciplinary evaluation including a diagnostic interview, symptom severity assessments with parent questionnaires, and IQ testing. We compared children with (n = 105) and without (n = 55) recommended methylphenidate treatment using Student's t test or Wilcoxon Mann-Whitney test and Chi-square or Fisher's test. Multivariate logistic regression was implemented to determine the respective influence of each variable on treatment recommendation. Recommendation to initiate methylphenidate treatment was associated with (1) ADHD combined presentation, (2) co-occurring Oppositional Defiant Disorder/Conduct Disorder (ODD/CD), Developmental Coordination Disorder (DCD) and Learning Disorder (LD), (3) clinical severity and impairment indicated on parent questionnaires, and (4) reduced perceptual reasoning. Using a multivariate regression model, ADHD combined presentation [combined versus predominantly hyperactive/impulsive and unspecified OR 4.52 (1.23-16.55), p = 0.023], age [OR 1.46 (1.14-1.88), p = 0.003], ODD/CD [OR 5.53 (2.19-14.01), p < 0.001], DCD [OR 4.22 (1.70-10.48), p = 0.002], PRI [OR 0.97 (0.94-0.99), p = 0.01] were significantly associated with recommendation of methylphenidate treatment. Our results indicate that clinicians' treatment decision-making complies with European guidelines and is furthermore associated with the type and severity of ADHD symptoms but also with co-occurring disorders.

Entities:  

Keywords:  Attention-deficit hyperactivity disorder (ADHD); Evidence-based treatment guidelines; Methylphenidate; Neuropsychological assessments; Stimulant medication

Mesh:

Substances:

Year:  2017        PMID: 28983797     DOI: 10.1007/s00787-017-1061-4

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  36 in total

1.  Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

2.  ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.

Authors:  Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser
Journal:  Pediatrics       Date:  2011-10-16       Impact factor: 7.124

3.  Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.

Authors:  I C K Wong; P Asherson; A Bilbow; S Clifford; D Coghill; R DeSoysa; C Hollis; S McCarthy; M Murray; C Planner; L Potts; K Sayal; E Taylor
Journal:  Health Technol Assess       Date:  2009-10       Impact factor: 4.014

Review 4.  The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.

Authors:  Tamara Pringsheim; Lauren Hirsch; David Gardner; Daniel A Gorman
Journal:  Can J Psychiatry       Date:  2015-02       Impact factor: 4.356

5.  Paediatricians' decision making about prescribing stimulant medications for children with attention-deficit/hyperactivity disorder.

Authors:  S-J Chow; E Sciberras; L H Gillam; J Green; D Efron
Journal:  Child Care Health Dev       Date:  2013-02-27       Impact factor: 2.508

6.  Short-term effectiveness of medication and psychosocial intervention in a cohort of newly diagnosed patients with inattention, impulsivity, and hyperactivity problems.

Authors:  Bruno Falissard; David Coghill; Aribert Rothenberger; Maria Lorenzo
Journal:  J Atten Disord       Date:  2009-09-18       Impact factor: 3.256

7.  The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study.

Authors:  Brooke S G Molina; Stephen P Hinshaw; James M Swanson; L Eugene Arnold; Benedetto Vitiello; Peter S Jensen; Jeffery N Epstein; Betsy Hoza; Lily Hechtman; Howard B Abikoff; Glen R Elliott; Laurence L Greenhill; Jeffrey H Newcorn; Karen C Wells; Timothy Wigal; Robert D Gibbons; Kwan Hur; Patricia R Houck
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-05       Impact factor: 8.829

8.  Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder.

Authors:  Chih-Ying Chen; Tobias Gerhard; Almut G Winterstein
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-04       Impact factor: 2.576

9.  Patient characteristics associated with treatment initiation among paediatric patients with Attention-Deficit/Hyperactivity Disorder symptoms in a naturalistic setting in Central Europe and East Asia.

Authors:  Jihyung Hong; Diego Novick; Tamás Treuer; William Montgomery; Virginia S Haynes; Shenghu Wu; Josep Maria Haro
Journal:  BMC Psychiatry       Date:  2014-10-30       Impact factor: 3.630

10.  Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway.

Authors:  David Coghill; Sarah Seth
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2015-11-19       Impact factor: 3.033

View more
  5 in total

1.  Towards a better understanding of the many facets of attention-deficit/hyperactivity disorder.

Authors:  Pieter J Hoekstra
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-03       Impact factor: 4.785

2.  Barriers and predictors of medication use for childhood ADHD: findings from a UK population-representative cohort.

Authors:  A E Russell; T Ford; G Russell
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-05-09       Impact factor: 4.328

3.  Maternal Sociodemographic Factors Are Associated with Methylphenidate Initiation in Children in the Netherlands: A Population-Based Study.

Authors:  K Cheung; H El Marroun; B Dierckx; L E Visser; B H Stricker
Journal:  Child Psychiatry Hum Dev       Date:  2021-04

4.  Individualizing the dosage of Methylphenidate in children with attention deficit hyperactivity disorder.

Authors:  Hoda Shirafkan; Javad Mahmoudi-Gharaei; Akbar Fotouhi; Seyyed Ali Mozaffarpur; Mehdi Yaseri; Mostafa Hoseini
Journal:  BMC Med Res Methodol       Date:  2020-03-11       Impact factor: 4.615

5.  Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder.

Authors:  Beate Oerbeck; Kari Furu; Pal Zeiner; Heidi Aase; Ted Reichborn-Kjennerud; Are Hugo Pripp; Kristin Romvig Overgaard
Journal:  J Child Adolesc Psychopharmacol       Date:  2020-07-14       Impact factor: 2.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.